ACET Adicet Bio, Inc.
Adicet Bio, Inc. (ACET) is expected to report earnings on November 4, 2026, after the market close. The consensus earnings estimate is a loss of $1.56 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -3.8% since its last earnings release on August 5, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Adicet Bio, Inc.
Adicet Bio Inc. is a biotechnology company. It engages in discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet Bio Inc., formerly known as RESTORBIO INC, is based in Calif.
Sector
Healthcare
Industry
Biotechnology